Akebia Therapeutics (AKBA) EBITDA (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of EBITDA data on file, last reported at -$4.7 million in Q1 2026.

• On a quarterly basis, EBITDA fell 134.75% year-over-year to -$4.7 million in Q1 2026; TTM through Mar 2026 was $5.3 million, a 124.02% increase from a year earlier, with the FY2025 full-year figure at $23.5 million, up 146.56% from the prior year.
• EBITDA for Q1 2026 stood at -$4.7 million, up from -$8.6 million in the prior quarter.
• Over the last five years, EBITDA for AKBA reached as high as $34.1 million in Q2 2022 and fell as low as -$59.6 million in Q1 2022.
• Historically, EBITDA has averaged -$9.3 million across 5 years, with a median of -$8.7 million in 2024.
• Across the five-year window, EBITDA slumped 1141.27% in 2024 and surged 261.48% in 2025, its largest moves.
• Year by year, EBITDA stood at -$4.9 million in 2022, then soared by 128.22% to $1.4 million in 2023, then slumped by 1141.27% to -$14.3 million in 2024, then soared by 40.22% to -$8.6 million in 2025, then jumped by 45.1% to -$4.7 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$4.7 million in Q1 2026, -$8.6 million in Q4 2025, and $4.4 million in Q3 2025.